• Product name

  • Description

    Rabbit polyclonal to PANK2
  • Host species

  • Tested applications

    Suitable for: WBmore details
  • Species reactivity

    Reacts with: Human
    Predicted to work with: Mouse, Rat, Sheep, Rabbit, Horse, Chicken, Guinea pig, Cow, Cat, Dog, Pig, Zebrafish
  • Immunogen

    Synthetic peptide, corresponding to a region within C terminal amino acids 459-508 (ERFGLPGWAV ASSFGNMMSK EKREAVSKED LARATLITIT NNIGSIARMC) of Human PANK2 (NP_705902).

  • Positive control

    • 293T cell lysate



Our Abpromise guarantee covers the use of ab128298 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use a concentration of 1 µg/ml. Predicted molecular weight: 63 kDa. Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.


  • Function

    May be the master regulator of the CoA biosynthesis.
  • Tissue specificity

  • Pathway

    Cofactor biosynthesis; coenzyme A biosynthesis; CoA from (R)-pantothenate: step 1/5.
  • Involvement in disease

    Defects in PANK2 are the cause of neurodegeneration with brain iron accumulation type 1 (NBIA1) [MIM:234200]; also known as pantothenate kinase-associated neurodegeneration (PKAN) or Hallervorden-Spatz syndrome (HSS). It is an autosomal recessive neurodegenerative disorder associated with iron accumulation in the brain, primarily in the basal ganglia. Clinical manifestations include progressive muscle spasticity, hyperreflexia, muscle rigidity, dystonia, dysarthria, and intellectual deterioration which progresses to severe dementia over several years. It is clinically classified into classic, atypical, and intermediate phenotypes. Classic forms present with onset in the first decade, rapid progression, loss of independent ambulation within 15 years. Atypical forms have onset in the second decade, slow progression, maintenance of independent ambulation up to 40 years later. Intermediate forms manifest onset in the first decade with slow progression or onset in the second decade with rapid progression. Patients with early onset tend to also develop pigmentary retinopathy, whereas those with later onset tend to also have speech disorders and psychiatric features. All patients have the 'eye of the tiger' sign on brain MRI.
    Defects in PANK2 are the cause of hypoprebetalipoproteinemia, acanthocytosis, retinitis pigmentosa, and pallidal degeneration (HARP) [MIM:607236]. HARP is a rare syndrome with many clinical similarities to NBIA1.
  • Sequence similarities

    Belongs to the type II pantothenate kinase family.
  • Cellular localization

    Cytoplasm and Mitochondrion.
  • Information by UniProt
  • Database links

  • Alternative names

    • 4933409I19Rik antibody
    • AI642621 antibody
    • C20orf48 antibody
    • Hallervorden Spatz syndrome antibody
    • HARP antibody
    • hPANK2 antibody
    • HSS antibody
    • MGC118448 antibody
    • MGC15053 antibody
    • mitochondrial antibody
    • NBIA1 antibody
    • PANK2 antibody
    • PANK2_HUMAN antibody
    • Pantothenate kinase 2 (Hallervorden Spatz syndrome) antibody
    • Pantothenate kinase 2 antibody
    • Pantothenate kinase 2 mitochondrial antibody
    • Pantothenic acid kinase 2 antibody
    • PKAN antibody
    • RP23 387C21.4 antibody
    see all


  • Anti-PANK2 antibody (ab128298) at 1 µg/ml + 293T cell lysate at 10 µg

    Predicted band size: 63 kDa

    Gel concentration: 12%


ab128298 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab128298.
Please use the links above to contact us or submit feedback about this product.

For licensing inquiries, please contact partnerships@abcam.com

Sign up